Active immunotherapy and alternative therapeutic modalities for Alzheimer's disease. Issue 1 (12th October 2020)

• Record Type: Journal Article
• Authors: Weninger, Stacie; Sperling, Bjorn; Alexander, Robert; Ivarsson, Magnus; Menzies, Fiona M.; Powchik, Peter; Weber, Christopher J.; Altar, C. Anthony; Crystal, Ronald G.; Haggarty, Stephen J.; Loring, Jeanne; Bain, Lisa J.; Carrillo, Maria C.
• Is Part Of: Alzheimer's & dementia. Volume 6:Issue 1(2020)
• Page Start: n/a
• Page End: n/a
• Publication Date: 2020-10-12
• Subjects: Dementia -- Periodicals; Dementia -- Treatment -- Periodicals; Alzheimer's disease -- Treatment -- Periodicals; Alzheimer's disease -- Periodicals; 616.831
• DOI: 10.1002/trc2.12090
• Languages: English
• ISSNs: 2352-8737

Abstract

Abstract: As knowledge of Alzheimer's disease (AD) progression improves, the field has recognized the need to diversify the pipeline, broaden strategies and approaches to therapies, as well as delivery mechanisms. A better understanding of the earliest biological processes of AD/dementia would help inform drug target selection. Currently there are a number of programs exploring these alternate avenues. This meeting will allow experts in the field (academia, industry, government) to provide perspectives and experiences that can help elucidate what the pipeline looks like today and what avenues hold promise in developing new therapies across the stages of AD. The focus here is on Active Immunotherapies and Alternative Therapeutic Modalities. This topic includes active vaccines, antisense oligomers, and cell‐based therapy among others, and highlights new clinical developments that utilize these modalities.